hdac inhibitor rec-2282
Generic: HDAC Inhibitor REC-2282
hdac inhibitor rec-2282: developed by 1 company · 1 clinical trial tracked.
hdac inhibitor rec-2282 evidence translation
What we can confirm
1 tracked trial
What it means
Source-backed records connect hdac inhibitor rec-2282 to RXRX; that link alone does not prove the drug works.
What to watch
Watch trial status, endpoints, and the next source-backed update.
BioSniper AIPage evidence connected
Prepared research question
How could hdac inhibitor rec-2282 → RXRX affect its developer, and what evidence supports the link?
Run cited research
Traceable citations · Unknowns marked
See linked entities and source evidence1 indications · 0 study sponsors
Related indications
Neurofibromatosis Type 2
Study sponsors
No additional listed-company sponsor is linked.
Development Pipeline (1)
| Company | Phase |
|---|---|
| RECURSION PHARMACEUTICALS, INC. (RXRX) Neurofibromatosis Type 2 | Phase 2/Phase 3 |
Clinical Trials (1)
A Two-staged, Phase 2/3, Randomized, Multicenter Study to Evaluate the Efficacy and Safety of REC-2282 in Participants With Progressive NF2 Mutated Meningiomas
Primary endpoint: Cohort A: Number of Participants with Progression-free survival (PFS) at 6 Months
InterventionalRandomizeddouble25 enrolledStarted 2022-06Completion 2025-0815 sites · United Kingdom, United StatesRecursion Pharmaceuticals Inc.
Frequently asked questions
Who is developing hdac inhibitor rec-2282?
hdac inhibitor rec-2282 is being developed by RECURSION PHARMACEUTICALS, INC..
How many clinical trials involve hdac inhibitor rec-2282?
BioSniper tracks 1 clinical trial involving hdac inhibitor rec-2282.